GLP-1 drugs treat alcohol addiction

A new study has found that semaglutide, the active ingredient in blockbuster weight-loss drugs like Ozempic, may significantly reduce alcohol consumption.

Researchers observed that patients with obesity who were taking the medication reported fewer 'heavy drinking days' and a marked decrease in cravings.

The findings suggest that GLP-1 receptor agonists could offer a new therapeutic pathway for treating alcohol use disorder.

While further clinical trials are needed, the results highlight the potential for these drugs to address a wider range of metabolic and behavioral health issues.